• Contact ArQule
  • About ArQule
  • Product R & D
    • Pipeline
    • Activated Checkpoint Therapy® Platform
    • C-Met/Cancer Survival Protein Platform
    • Glossary
  • Clinical Trials
  • Investors and Media
  • Careers
Home : Product R & D : Pipeline

Pipeline

Print Version
Product Program Partner Research Pre-Clinical Development Phase I Phase II Phase III
ONCOLOGY
ARQ 197 C-Met Inhibitor Daiichi Sankyo4
Kyowa Hakko5
ARQ 501 E2F1 Pathway Activator  
ARQ 761 E2F1 Pathway Activator  
 
ARQ 621 Eg5 Inhibitor
BRAF Kinase Inhibitor
Selective, ATP-exclusionary Kinase Inhibitors Arqule Kinase Inhibitor Platform (AKIPTM) Daiichi Sankyo6
and Internal Program
NON-ONCOLOGY

ArQule has provided compounds to certain pharmaceutical companies that are pursuing development programs in non-oncology indications. As material information becomes available regarding the status of these programs, ArQule will provide updates through its press releases or filings.

Portfolio Updated July 2008

1 Pre-GLP toxicology testing
2 Post-initation of GLP toxicology testing
3 Designation follows initation of first patient enrollment and dosing
4 U.S., Europe, South America and the rest of the world, excluding Japan and select Asian countries
5 Japan and select Asian countries
6 Two targets in oncology; other applications for additional collaborations under consideration

© ArQule, 2006 | Terms and Conditions: Purchasing | Terms of Use